Search engine for discovering works of Art, research articles, and books related to Art and Culture
ShareThis
Javascript must be enabled to continue!

Nature Products Enhance NKG2D Ligands Expression of CD123+CD34+CD38− Leukemia Stem Cells for Stimulating Cytotoxicity of NKG2D+ Cells to Themselves

View through CrossRef
Abstract CD123+CD34+CD38− leukemia cells regarded as leukemia stem cells, not only refractory to chemotherapeutics but also resistant to immune response such as cytotoxicity of prime natural killer cells, usually lead leukemia to relapse. It is essential to eliminate leukemia stem cells at utmost for cure. Here we would observe whether nature products could enhance CD123+CD34+CD38− leukemia cells to express NKG2D ligands for arousing cytotoxicity of NKG2D+ cells to thoroughly eliminate leukemia stem cells. First, CD123+CD34+CD38− leukemia cells, isolated from human acute leukemia cell line KG1a, whose MLL gene was broken apart and rearranged, of which over 60% were in G0 phase of cell cycle, which could form about 80 colonies per 1000 cells in methylcellulose after 21 days. What’s more, they were worse than CD123+CD34+CD38+ leukemia cells on resistance to cytotoxicity of natural killer cells(Killed ratio <19%). CD123+CD34+CD38− leukemia cells from KG1a had characteristic of defined leukemia stem cells. Then, NKG2D+ cells from human peripheral blood monocytes were stimulated by cytokines and CpG, whose cytotoxicity against K562 cells reached (96.5±1.23)% analyzed by LDH releasing assay, suggesting NKG2D+ cells had better cytotoxicity than prime natural killer cells (69.31±8.45)%. However, cytotoxicity of NKG2D+ cells against CD123+CD34+CD38− leukemia stem cells was only(49.17±3.90)%, still higher than of prime natural killer cells (19±2.63)%. Therefore, whether to arouse cytotoxicity of NKG2D+ cells to deplete leukemia stem cells become essential. Finally, three kinds of nature products would be selected, including resveratrol (RV, a polyphenol found in berries), matrine and arsenic trioxide (ATO), which could decrease proliferation and survival of CD123+CD34+CD38− leukemia cells and whose 50% effective concentration (EC50) were respectively 56μM, 500μg/ml and 4.0μM. Importantly, EC50 of resveratrol could up regulate NKG2D ligands ULBP1 to (53.28±8.60)%, ULBP2 to (36.54±11.45)% and ULBP3 to (65.08±14.44)% on the surface of CD123+CD34+CD38− leukemia cells, and stimulate cytolytic ability of NKG2D+ cells, so that cytotoxicity of NKG2D+ cells against them reached from (49.17±3.90)% to (92.33±2.63)%. Similarly to matrine and arsenic trioxide, they could each up regulate ULBP2 from to 9.71±2.37% and ULBP1 to 24.38±3.65%, resulting in cytotoxicity of NKG2D+ cells against them reaching to 73.20±3.41% and 55.70±0.53%. In conclusions, cytotoxicity of NKG2D+ cells was better than of prime natural killer cells against not only K562, but also CD123+CD34+CD38− leukemia cells, which had characteristic of leukemia stem cells, even to resist killing of prime natural killer cells. Nature products, resveratrol, matrine and arsenic trioxide, could enhance NKG2D ligands expression of CD123+CD34+CD38− leukemia stem cells for stimulating cytotoxicity of NKG2D+ cells to leukemia stem cells. This finding could provide a new strategy for eliminate leukemia stem cells.
American Society of Hematology
Title: Nature Products Enhance NKG2D Ligands Expression of CD123+CD34+CD38− Leukemia Stem Cells for Stimulating Cytotoxicity of NKG2D+ Cells to Themselves
Description:
Abstract CD123+CD34+CD38− leukemia cells regarded as leukemia stem cells, not only refractory to chemotherapeutics but also resistant to immune response such as cytotoxicity of prime natural killer cells, usually lead leukemia to relapse.
It is essential to eliminate leukemia stem cells at utmost for cure.
Here we would observe whether nature products could enhance CD123+CD34+CD38− leukemia cells to express NKG2D ligands for arousing cytotoxicity of NKG2D+ cells to thoroughly eliminate leukemia stem cells.
First, CD123+CD34+CD38− leukemia cells, isolated from human acute leukemia cell line KG1a, whose MLL gene was broken apart and rearranged, of which over 60% were in G0 phase of cell cycle, which could form about 80 colonies per 1000 cells in methylcellulose after 21 days.
What’s more, they were worse than CD123+CD34+CD38+ leukemia cells on resistance to cytotoxicity of natural killer cells(Killed ratio <19%).
CD123+CD34+CD38− leukemia cells from KG1a had characteristic of defined leukemia stem cells.
Then, NKG2D+ cells from human peripheral blood monocytes were stimulated by cytokines and CpG, whose cytotoxicity against K562 cells reached (96.
5±1.
23)% analyzed by LDH releasing assay, suggesting NKG2D+ cells had better cytotoxicity than prime natural killer cells (69.
31±8.
45)%.
However, cytotoxicity of NKG2D+ cells against CD123+CD34+CD38− leukemia stem cells was only(49.
17±3.
90)%, still higher than of prime natural killer cells (19±2.
63)%.
Therefore, whether to arouse cytotoxicity of NKG2D+ cells to deplete leukemia stem cells become essential.
Finally, three kinds of nature products would be selected, including resveratrol (RV, a polyphenol found in berries), matrine and arsenic trioxide (ATO), which could decrease proliferation and survival of CD123+CD34+CD38− leukemia cells and whose 50% effective concentration (EC50) were respectively 56μM, 500μg/ml and 4.
0μM.
Importantly, EC50 of resveratrol could up regulate NKG2D ligands ULBP1 to (53.
28±8.
60)%, ULBP2 to (36.
54±11.
45)% and ULBP3 to (65.
08±14.
44)% on the surface of CD123+CD34+CD38− leukemia cells, and stimulate cytolytic ability of NKG2D+ cells, so that cytotoxicity of NKG2D+ cells against them reached from (49.
17±3.
90)% to (92.
33±2.
63)%.
Similarly to matrine and arsenic trioxide, they could each up regulate ULBP2 from to 9.
71±2.
37% and ULBP1 to 24.
38±3.
65%, resulting in cytotoxicity of NKG2D+ cells against them reaching to 73.
20±3.
41% and 55.
70±0.
53%.
In conclusions, cytotoxicity of NKG2D+ cells was better than of prime natural killer cells against not only K562, but also CD123+CD34+CD38− leukemia cells, which had characteristic of leukemia stem cells, even to resist killing of prime natural killer cells.
Nature products, resveratrol, matrine and arsenic trioxide, could enhance NKG2D ligands expression of CD123+CD34+CD38− leukemia stem cells for stimulating cytotoxicity of NKG2D+ cells to leukemia stem cells.
This finding could provide a new strategy for eliminate leukemia stem cells.

Related Results

PARP1 inhibition sensitizes AML to CD123 CAR-NK cells via immunophenotypic remodeling
PARP1 inhibition sensitizes AML to CD123 CAR-NK cells via immunophenotypic remodeling
Abstract Background:Acute myeloid leukemia (AML) is an aggressive hematologic malignancy driven by leukemic stem cells (...
CD38 as a Prognostic Factor in Chinese Patients with Chronic Lymphocytic Leukaemia.
CD38 as a Prognostic Factor in Chinese Patients with Chronic Lymphocytic Leukaemia.
Abstract B-cell chronic lymphocytic leukemia (CLL) is the most common type of adult leukemia in the Western world, however, infrequent in the Eastern. Although the m...
Isolation and Characterization of a CD34+ Sub-Clone in B-Cell Lymphoma
Isolation and Characterization of a CD34+ Sub-Clone in B-Cell Lymphoma
Non-Hodgkin's lymphoma (NHL) is the most common hematological malignancy in the US. Many types remain incurable despite response to initial therapy and achievement of complete remi...
Characterizing CD38 expression in terminally differentiated B cells using variable lymphocyte receptor B tetramers
Characterizing CD38 expression in terminally differentiated B cells using variable lymphocyte receptor B tetramers
IntroductionCD38 is an ectoenzyme receptor found on hematopoietic cells and its expression is used in the flow cytometric analysis of sub-populations of circulating B cells among p...
Stem cells
Stem cells
What is a stem cell? The term is a combination of ‘cell’ and ‘stem’. A cell is a major category of living thing, while a stem is a site of growth and support for something else. In...
Combinatorial Antigen Targeting Strategy for Acute Myeloid Leukemia
Combinatorial Antigen Targeting Strategy for Acute Myeloid Leukemia
Introduction: Efforts to safely and effectively treat acute myeloid leukemia (AML) by targeting a single leukemia associated antigen with chimeric antigen receptor T (CAR T) cells ...

Back to Top